IN2014DN09717A - - Google Patents

Info

Publication number
IN2014DN09717A
IN2014DN09717A IN9717DEN2014A IN2014DN09717A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A IN 9717DEN2014 A IN9717DEN2014 A IN 9717DEN2014A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A
Authority
IN
India
Prior art keywords
pdgf
antibodies
inhibiting
binding
pdgfra
Prior art date
Application number
Other languages
English (en)
Inventor
Claudia Fromond
Hoa Thu Ngo
Richard Zwaal
Sofie Notebaert
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of IN2014DN09717A publication Critical patent/IN2014DN09717A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9717DEN2014 2012-04-24 2014-11-18 IN2014DN09717A (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
IN2014DN09717A true IN2014DN09717A (he) 2015-07-31

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9717DEN2014 IN2014DN09717A (he) 2012-04-24 2014-11-18

Country Status (13)

Country Link
US (1) US9884910B2 (he)
EP (1) EP2841454A1 (he)
JP (1) JP2015515487A (he)
KR (1) KR20150005631A (he)
CN (1) CN104321343A (he)
AU (1) AU2013254690B2 (he)
BR (1) BR112014025560A2 (he)
CA (1) CA2871528A1 (he)
IN (1) IN2014DN09717A (he)
MX (1) MX2014012843A (he)
NZ (2) NZ724395A (he)
RU (1) RU2014140116A (he)
WO (1) WO2013160359A1 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
EP3373967B9 (en) * 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
CN109843918B (zh) * 2016-07-01 2023-08-25 旁分泌疗法公司 用于pdgf-cc抑制的方法和组合物
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
SG11202004940VA (en) * 2017-12-04 2020-06-29 Salvat Lab Sa Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
EP1123408A1 (en) 1998-09-30 2001-08-16 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
WO2000034474A2 (en) 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (en) 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
CN1419413A (zh) * 2000-03-28 2003-05-21 路德维格癌症研究所 表达血小板衍生生长因子c(pdgf－c)的非人转基因动物及其应用
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP1660135B1 (en) * 2003-07-25 2009-06-03 ZymoGenetics, Inc. Method of treating hepatocellular carcinoma
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2007124308A2 (en) 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies

Also Published As

Publication number Publication date
KR20150005631A (ko) 2015-01-14
NZ724395A (en) 2018-03-23
US20150232546A1 (en) 2015-08-20
RU2014140116A (ru) 2016-06-10
AU2013254690B2 (en) 2017-12-07
CA2871528A1 (en) 2013-10-31
MX2014012843A (es) 2017-01-23
JP2015515487A (ja) 2015-05-28
NZ700274A (en) 2016-10-28
WO2013160359A1 (en) 2013-10-31
BR112014025560A2 (pt) 2017-07-04
US9884910B2 (en) 2018-02-06
CN104321343A (zh) 2015-01-28
EP2841454A1 (en) 2015-03-04
AU2013254690A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
TN2015000396A1 (en) Antibody drug conjugates
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
IN2014DN09717A (he)
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
WO2014163714A3 (en) Antibody drug conjugates
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
NZ733664A (en) Antibodies that bind human c6 and uses thereof
IL232339A0 (he) נוגדני 32rf10c, ושימושים בהם לטיפול בסרטן
IL232340A0 (he) נוגדני lsr, ושימושים בהם לטיפול בסרטן